

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

12<sup>th</sup> March, 2025

To,

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	---

**Sub: Press Release – Alkem launches generic empagliflozin and its combinations in India under the brand name “Empanorm”.**

Dear Sir(s)/Madam,

This is to intimate you that Alkem Laboratories Limited (the “Company”) launches generic empagliflozin and its combinations in India under the brand name “Empanorm”.

A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

**Manish Narang**

**President- Legal, Company Secretary and Compliance Officer**

## Press Release

### **Alkem Laboratories launches generic empagliflozin and its combinations in India under the brand name “Empanorm”**

- *Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure*
- *Alkem is introducing anti-counterfeit band and important patient education information on empagliflozin packs*
- *Alkem is offering empagliflozin in a smaller tablet size, making it convenient for patients*

**Mumbai, March 12, 2025:** Alkem Laboratories Ltd (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries), today announced the launch of generic empagliflozin and its combinations in India under the brand name “Empanorm” at prices that are approximately 80% lower than the innovator products.

Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicated for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). Alkem’s generic empagliflozin and its combinations are bioequivalent to innovator products.

With a patient-centric approach, Alkem has introduced anti-counterfeit security band on the pack of Empanorm, as well as comprehensive patient education information, including basic details on diabetes management in Hindi and English with infographics, and QR codes that provide prescribing information and additional patient education information on diabetes, heart failure, and chronic kidney disease in 11 languages.

Keeping patient-convenience in mind, Alkem is offering the medicine in a considerably smaller tablet size than the innovator products.

Alkem’s generic empagliflozin is available under the brand name “Empanorm” and its combinations namely: (i) empagliflozin and linagliptin is available under the name “Empanorm L”; (ii) empagliflozin and sitagliptin is available under the name “Empanorm Duo” and “Alsita E”; and (iii) empagliflozin and metformin is available under the name “Empanorm M”.

*Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, “As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone. This globally-accepted molecule has transformed diabetes care with its additional benefits in managing chronic kidney disease and cardiovascular health. Leveraging Alkem’s strong distribution network, we aim to make this therapy widely available, enhancing treatment accessibility and improving health outcomes for patients across the country.”*

**About Alkem:**

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centers across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit [www.alkemlabs.com](http://www.alkemlabs.com) and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#).

<b>Contacts</b>	
<b>Media:</b> Isha Trivedi <a href="mailto:alkemcorpcomm@alkem.com">alkemcorpcomm@alkem.com</a> +91-98925 90003	<b>Investors:</b> Purvi Shah <a href="mailto:purvi.shah@alkem.com">purvi.shah@alkem.com</a> +91-84337 00890